Treatment of adverse digitalis effects by hemoperfusion through columns with antidigoxin antibodies bound to agarose polyacrolein microsphere beads.
Ten patients with an array of moderate to severe adverse effects resulting from digitalis were effectively treated by hemoperfusion through small columns which contained antidigoxin antibodies bound to polyacrolein microspheres in agarose macrospheres (APAMB). The procedure was well tolerated. There was no detectable damage to formed blood elements and no changes in electrolytes, liver enzymes, or other related biochemical parameters. Despite some theoretic considerations to the contrary, the removal of a relatively small load of digoxin resulted in amelioration of the clinical symptoms and ECG abnormalities associated with digitalis. No rebound phenomena of intoxication or posthemoperfusion increase in digoxin serum levels were noted over the subsequent 5 to 6 days. A further increase in the capacity of the columns may render this method a safe and convenient emergency procedure for patients with digitalis toxicity.
D000171:Acrolein; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies; D001672:Biocompatible Materials; D004077:Digoxin / Q000097:blood / Q000276:immunology / Q000506:poisoning*; D005260:Female; D006331:Heart Diseases / Q000188:drug therapy*; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D011108:Polymers; D012685:Sepharose
D000906:Antibodies; D001672:Biocompatible Materials; D011108:Polymers; C029975:polyacrolein; D004077:Digoxin; D000171:Acrolein; D012685:Sepharose